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Abstract
Background: Quantitative in vivo imaging of tau pathologies potentially improves diagnostic accuracy of
neurodegenerative tauopathies and would facilitate evaluation of disease-modifying drugs targeting tau lesions in
these diseases. Tau pathology can be quantified by reference tissue models without arterial blood sampling when
reference tissue devoid of target binding sites is available. The cerebellar cortex has been used as a reference
region in analyses of tau positron emission tomography (PET) data in Alzheimer’s disease (AD). However, in a
significant subset of tauopathies such as progressive supranuclear palsy and corticobasal degeneration, tau
accumulation may occur in diverse brain regions including the cerebellar cortex. This hampers selection of a
distinctive reference region lacking binding sites for a tau PET ligand. The purpose of this study was to develop a
new method to quantify specific binding of a PET radioligand, 11C-PBB3, to tau deposits using reference voxels
extracted from cortical gray matter, which have a low likelihood of containing tau accumulations.
Methods: We reanalyzed 11C-PBB3 PET data of seven mild AD patients (ADs) and seven elderly healthy control
subjects (HCs) acquired in a previous study. As a standard method, parametric images of binding potential (BPND)
were initially generated using reference tissue manually defined on the cerebellar cortex. We then constructed a
frequency histogram of BPND values in these parametric images and selected cortical gray matter voxels contained
in a certain range of the histogram with a low likelihood of having 11C-PBB3 binding sites. Finally, these reference
voxels were used for generating new BPND parametric images.
Results: Reference tissue voxels defined by the histogram analysis spread throughout the cortical gray matter of
AD and HC brains. The BPND values determined by our new method correlated very well with those estimated by
the standard method (r2 = 0.94), although the binding estimates by the current method were slightly higher
by ~0.14 than those by the standard method.
Conclusions: We developed and validated a new method enabling quantification of tau lesions that can
accumulate in the cerebellum and other extensive brain areas. This method may be applicable to all
tauopathy subtypes and various tau PET ligands besides 11C-PBB3.
Trial registration: The number is UMIN000009052
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Background
Fibrillary tau aggregates are hallmark neuropathol-
ogies in diverse neurodegenerative disorders, including
Alzheimer’s disease (AD), progressive supranuclear
palsy, corticobasal degeneration, and Pick’s disease,
collectively referred to as tauopathies. Imaging of tau
lesions in living tauopathy patients has been enabled
recently, and in vivo quantification of tau pathologies
would improve accuracy of diagnosing these disorders
and facilitate objective assessments of anti-tau treatments
capable of modifying the disease process. Recently, we
developed a radioligand, 11C-PBB3 (2-((1E,3E)-4-(6-(11C-
methylamino)pyridin-3-yl)buta-1,3-dienyl) benzo[d]thia-
zol-6-ol), for tau imaging with positron emission
tomography (PET) [1] and established methods for
quantification of tau pathologies in the brains of AD
patients using 11C-PBB3 [2].
With 11C-PBB3 PET, AD tau pathology could be
accurately quantified by a dual-input graphical analysis
with blood data or by an original multilinear reference
tissue model (MRTMO) without blood data [2]. Nonin-
vasive PET assays without blood sampling are of particu-
lar significance for safely conducting scans in demented
subjects, highlighting advantages of MRTMO. Reference
tissue models including MRTMO employ time-activity
data in a brain area lacking specific binding components
as input functions, and the cerebellum has been utilized
as reference tissue in AD since tau does not markedly
accumulate in the cerebellar cortex [3]. In other tauopa-
thies, such as progressive supranuclear palsy and cortico-
basal degeneration, however, tau deposits may be found in
extensive cortical and subcortical regions including the
cerebellar cortex, cerebellar dentate nucleus, brainstem,
thalamus, and basal ganglia [4–6]. This impedes selection
of a distinctive brain region devoid of tau ligand binding
sites as reference tissue [7, 8]. Thus, a method to extract a
reference on a voxel basis needs to be developed in case a
single volume with no or minimal binding components
cannot be defined for PET quantification.
The purpose of the present study was to develop a
new method to quantitatively measure specific binding
of 11C-PBB3 to tau aggregates using reference voxels
extracted from cortical gray matter, which have a low
likelihood of containing tau fibrils.
Methods
11C-PBB3 PET data obtained from seven mild AD
patients (ADs) and seven elderly healthy control subjects
(HCs) in a previous study was reanalyzed (three men/
four women for both groups, aged 76 ± 7 years for ADs
and 70 ± 6 years for HCs, mean ± standard deviation
(SD)) [2]. In brief, mini-mental state examination scores
[9] were 19.4 ± 2.4 in ADs and 28.4 ± 2.2 in HCs. All
HCs were free of major medical and neuropsychiatric ill-
nesses. All ADs were positive and all HCs were negative
for amyloid-β plaques according to amyloid PET with
11C-Pittsburgh compound B. This study was approved by
the Radiation Drug Safety Committee and the Institu-
tional Review Board of National Institute of Radiological
Sciences of Japan. Written informed consent or assent
was obtained from all subjects. The study was registered
with University Hospital Medical Information Network
Clinical Trials Registry (UMIN000009052).
11C-PBB3 PET imaging was performed as previously
described [2]. After an intravenous injection of 11C-
PBB3 (injected dose, 399 ± 45 MBq; specific activity,
88 ± 32 GBq/μmol), 70-min dynamic PET scans were
conducted using an ECAT Exact HR+ system (devel-
oped by CTI, Knoxville, TN, USA, and distributed by
Siemens Healthcare, Erlangen, Germany). Arterial blood
samples were manually obtained 30 times during the PET
scan. Each blood sample was centrifuged, and radioactivity
concentrations in the whole blood and plasma were
measured. The plasma fractions of the parent and its
radiometabolites were determined by high-performance li-
quid chromatography from six samples. Two-exponential
functions were used to interpolate the fraction of the
parent and radiometabolites to obtain input functions.
We initially generated parametric images of binding
potential ( BPND ) using a standard reference tissue
method. A reference region was manually defined on
the cerebellar cortex of coregistered magnetic reson-
ance images. Then, parametric images for BPND were
generated for each subject by MRTMO and the cere-
bellar cortex reference [2]. This approach was based
on the assumption that specific radioligand binding
was negligible in cerebellar cortical gray matter of the
AD brains.
We subsequently applied a new method to define
reference voxels in cortical gray matter that have a
low likelihood of radioligand binding, on the assump-
tion that not all gray matter voxels are affected by
tau pathology in most of tauopathies. A frequency
histogram of BPND values was constructed from all
voxels of the parametric images generated by the
abovementioned standard method (Fig. 1). The histo-
gram of each HC was fitted with a Gaussian distribu-
tion function, and mean full width at half maximum
(FWHM) of the Gaussian curve in seven HCs was
calculated. We defined the reference tissue as a pool
of voxels that had BPND values above mean minus 2
standard deviation (SD) at a range of the mean
FWHM (mean ± SD = 0.33 ± 0.03) on the frequency
histogram (Fig. 1), followed by more robust selection of
voxels in cortical gray matter with the aid of MR seg-
mentation using statistical parametric mapping (SPM12;
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Wellcome Trust Centre for Neuroimaging, London,
UK). The rationale for selecting the mean BPND range
of FWHM was to obtain an adequate total volume of
the reference tissue (almost all cortical voxels in
HCs), which should provide a very stable reference
tissue input function for BPND estimation. The lowest
point of this range was set at the −2 SD limit to
threshold out noisy voxels. Then, we defined refer-
ence tissue in the cortical gray matter of the AD
brains by pooling voxels with BPND above −2 SD of
ADs at a range of the mean FWHM of HCs (=0.33).
Finally, a BPND parametric image was generated for
each subject by MRTMO and an individual time-
activity curve that were generated by averaging data
in these reference voxels. We extracted reference vox-
els that have a low likelihood of tau binding only
from the cortical voxels. In this regard, we could also
have included the white matter voxels with a low
likelihood of tau binding. However, for 11C-PBB3,
non-displaceable (nonspecific) binding appears to be
different between the gray and white matters [2].
Therefore, we extracted reference voxels only from
the cortex in the present study.
In order to compare the two reference tissue definition
approaches, we applied the same sets of regions of interest
(ROIs) to the parametric images generated by the cerebel-
lar cortical reference tissue and extracted reference tissue
methods to obtain mean BPND values in each ROI as de-
scribed in the previous paper [2]. For ADs, we generated
three to four cerebral cortical ROIs by pooling voxels clas-
sified into those with high (>0.3, high), medium (0.15–0.3,
middle), low (0–0.15, low), and no (<0, nonbinding) BPND
values on the preliminary parametric images generated by
applying coregistered cerebral cortical masks (two AD
subjects did not have any significant number of high B
PND voxels, and therefore, three cortical ROIs for these
two subjects and four cortical ROIs for the other five
AD subjects). These four sets of ROIs had a sample
volume of 12 ± 6, 50 ± 27, 103 ± 35, and 188 ± 64 cm3,
respectively. For HCs, we created one large entire cor-
tical ROI (440 ± 34 cm3), since cerebral cortical BPND
was uniformly low.
To investigate difference in the amount of nonspecific
binding between the two reference tissues, we measured
distribution volumes in these tissues. A dual-input graph-
ical analysis with an arterial input function was used to
measure α (a slope of a regression in the graphical
analysis, which equals to the weighted sum of total distri-
bution volume of parent and radiometabolites; see Eqs. 1
and 3 in [2]).
Results
Reference tissue voxels with a low likelihood of noticeable
tau deposition selected by our new method broadly spread
in cerebral and cerebellar cortical gray matters of the AD




















Fig. 1 Histogram of BPND values in a parametric image of a
representative HC subject. A frequency histogram was constructed
using BPND values in all voxels (blue area). Purple line indicates the
mean FWHM of a Gaussian distribution fit in HCs (0.33). Voxels with
BPND values above mean −2 SD at a range of the mean FWHM
(purple area) were selected to generate a reference tissue. A
frequency histogram of BPND values in the manually defined






Fig. 2 Reference voxels extracted from cortical gray matter of a
representative Alzheimer’s disease patient (AD, top row) and a
healthy control subject (HC, bottom row). On transaxial (left) and
coronal (right) BPND parametric images, areas surrounded by red lines
indicate voxels with BPND values above mean −2 SD in this subject
for a range of the mean FWHM in HCs (0.33). To obtain reference
voxels (light green area) extracted from cerebral and cerebellar
cortical gray matter, we intersected the red area with gray matter
voxels segmented on magnetic resonance images
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voxels in ADs and HCs were 225 ± 52 and 418 ± 66 cm3,
respectively.
To validate the applicability of this method to quantifi-
cation of tau lesions in AD, we compared BPND values
estimated by MRTMO with reference tissues defined by
the standard and new methods. The mean time-activity
curve in the pooled reference voxels yielded by the new
method was slightly lower than that in the cerebellar
cortical ROI by the standard method (Fig. 3). The
two BPND values were tightly correlated with each
other (r2 = 0.94, Fig. 4), although the BPND values
calculated by the new method were slightly higher by ~0.14
than those estimated by the standard method using a
cerebellar cortical ROI.
We also performed a dual-input graphical analysis of
PET images in these subjects with arterial input func-
tions to measure α of the reference tissues defined in
two ways. The α values in the reference tissue defined by
the new method (0.20 ± 0.05 in ADs and 0.16 ± 0.02 in
HCs) were slightly lower than those defined by the
standard method with the cerebellar cortical ROI
(0.22 ± 0.05 in ADs and 0.19 ± 0.02 in HCs), while
they were well correlated with each other (r2 = 0.94, Fig. 5).
These results suggest that BPND values estimated by
MRTMO with the new reference voxels are valid, but the
non-displaceable distribution of radioligands in these
voxels of the HC and AD brains was slightly lower than
that in the cerebellar cortex, resulting in slightly higher
BPND values in the target regions.
Discussion
We documented development of a new method to quantify
specific binding of 11C-PBB3 to tau pathologies using refer-
ence voxels extracted from cortical gray matter. As BPND
values calculated using extracted reference voxels were well
correlated with those calculated using cerebellar cortical
reference regions in mild ADs and HCs, the new reference
method may be used for patients with other tauopathies.
Tau accumulation in the cortical gray matter of other
tauopathies is often less extensive than that in AD resulting






















Fig. 3 Mean time-activity curves of the new reference tissue
extracted from cortical gray matter (filled circle) and standard
cerebellar cortical reference (open circle). Data represent mean ± SD
of all subjects






















Fig. 4 A correlation of BPND values estimated by MRTMO with the
new pooled voxels and standard cerebellar cortical references.
A good correlation was observed between parameter estimates
by the two methods (r2 = 0.94). The data points represent BPND
values in each ROI of ADs (3–4 ROIs each) and HCs (one ROI
each). Straight line indicates line of identity


















Fig. 5 Correlation of α values in two reference regions. α values in
the reference voxels extracted from cortical gray matter showed a
good correlation with those in the cerebellar cortical ROI (r2 = 0.94).
Straight line indicates line of identity
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in extraction of large volumes of reference tissue pro-
viding reliable input functions for the reference tissue
model BPND estimations.
The BPND values estimated using the extracted refer-
ence voxels were slightly higher than those estimated
using cerebellar cortical ROIs. This difference is attribut-
able to the difference in nonspecific binding of the radi-
oligand between the two reference tissues. In addition,
radioactivity in cerebellar cortical ROIs can be overesti-
mated by spillover of radioactivity from veins in and
adjacent to the cerebellar cortex. In the previous study,
we found that non-displaceable distribution volumes in
the cerebral cortex were 11–15 % lower than those in
the cerebellar cortex of the AD and HC brains [2].
Similarly, we found in this study that α was 11–15 %
lower in the extracted reference tissue, which con-
sisted of gray matter from the combined cerebral and
cerebellar cortices, than in the cerebellar cortex only
reference tissue.
The lower nonspecific binding in the extracted refer-
ence voxels may provide the reason why the cerebellar
cortical reference tissue constantly gave slightly negative
BPND values in the “nonbinding” cortical gray matter
regions without tau accumulation (Fig. 4; −0.14 ± 0.05 in
HCs and −0.13 ± 0.03 in ADs). However, the use of the
extracted reference voxels resulted in BPND values in
these nonbinding regions close to zero (0.03 ± 0.02 in
HCs and −0.03 ± 0.03 in ADs). Thus, the new method
appears superior to the standard method in estimating
BPND values in the cerebral cortex, although BP

ND may be
biased in subcortical areas and white matter, where non-
specific binding may be different from that in the
extracted cortical reference tissue.
We also found that α in the extracted reference
regions was higher in ADs than in HCs. This finding
may stem from low-level contamination of the extracted
reference tissue with voxels containing tau lesions in ADs.
Theoretically, it is not possible to perfectly discriminate
voxels without tau accumulation from those with accumu-
lation in the AD brain by the frequency histogram. Even if
the reference tissue is not devoid of specific binding
sites, MRTMO calculates a target-to-reference tissue
ratio minus 1 at equilibrium, resulting in underesti-
mation of BPND.
To apply the current method to the quantification of
tau accumulation in the patients with tauopathies, prior
knowledge of HC histograms is required to determine
the range of BPND values to extract reference voxels
from the histogram of the patients. The FWHM of the
voxel frequency distribution of BPND values across the
brain cortex of the patients was much wider in ADs than
that in HCs, because the frequency histogram in the
former includes voxels with tau accumulation as opposed
to the frequency distribution with all voxels with no tau
accumulation in the latter. Therefore, the range of BPND
values for a particular subject cannot be determined using
only the FWHM of that subject if the subject is expected
to show tau accumulation, because tau accumulations
might be underestimated if we used the FWHM BPND
range from that person due to the reference tissue being
not devoid of tau binding. However, not all cortical voxels
are tau binding positive in tauopathy brains, and this
method is intended to extract those voxels with a low like-
lihood of tau accumulation to be used as the reference
tissue. For this reason, the current method requires the
mean FWHM of HCs as the lower range of BPND with an
assumption that those voxels in this range should have a
low likelihood of tau accumulation.
Although we used manually defined reference regions
on the cerebellar cortex, the initial parametric images
can be generated using automatically segmented cerebel-
lar cortices. The final target BPND values will be the
same for the two reference region selection methods. It
is because that the shape of histograms will be the same
regardless of the choice of the methods to define the
cerebellar cortical reference region for the same subject.
If the cerebellar cortical reference ROI includes tau
binding voxels, the origin of the histogram (the point of
BPND = 0) on the horizontal BP

ND bin axis will be shifted
to the right (i.e., the histogram will be shifted to the left),
but the histogram will have the same BPND voxel distri-
bution shape as in the case where no tau binding voxels
are included in the cerebellar cortical ROI. That is, B
PND in some target regions can have negative values if
this is the final step. However, this step is a preliminary
one in the current method. In the current method, we
extract reference voxels that fall under the lower end of
the histogram range, which sets the mean BPND in this
range to be zero in the regenerated BPND parametric
images.
Of note is that the commonly used standardized uptake
value ratio (SUVR) method also requires identification of
reference tissue regions devoid of tau binding to be used
as the denominator for calculating the target-to-reference
tissue SUV ratios. Therefore, the lack of distinctively iden-
tifiable reference regions in tauopathies presents the same
problem as for the BPND method. In this sense, the
current method of extracting voxels with a low likelihood
of tau binding might also be applicable to the SUVR
method by generating voxel SUV frequency histograms in
both healthy controls and tauopathy patients.
Conclusions
In conclusion, we demonstrated the validity of a new
method to assess tau pathologies with 11C-PBB3 using
cortical gray matter reference tissue, by the use of
Kimura et al. EJNMMI Research  (2016) 6:24 Page 5 of 6
PET data in ADs and HCs. This method may be
applicable to patients with non-AD tauopathies with
diverse tau distribution.
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BPND : binding potential;
11C-PBB3: 2-((1E,3E)-4-(6-(11C-methylamino)pyridin-3-
yl)buta-1,3-dienyl) benzo[d]thiazol-6-ol; AD: Alzheimer’s disease; FWHM: full
width at half maximum; HC: healthy control; MRTMO: original multilinear
reference tissue model; PET: positron emission tomography; SD: standard
deviation.
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